what is the difference between glp-1 and glp-2 and glp-3 GLP-1, GLP-2, GLP-1, GLP-2, GLP-3, use them

The prevalence of patients with ME/CFS in the USA is estimated to be between 1.7 million and 3.38 million [6], corresponding to a range from 0.1 to 2.5% in the general population, depending on the diagnostic criteria applied [7]

But their experience is most likely due to the placebo effect instead of the peptides themselves: Research linking GH supplements with better sleep shows it helps only in the case of people with a true GH deficiency

Unlike traditional L-carnitine, which the body can make itself, acetyl-L-carnitine is added another acetyl group

contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Risk of diabetic retinopathy complications in patients with pre-existing retinopathy Potential for acute kidney injury, particularly related to dehydration Caution or avoidance in severe gastroparesis or severe gastrointestinal disease Suicidality warning for weight-management indications (Wegovy, Saxenda) Potential for altered absorption of oral medications due to delayed gastric emptying In older adults with cognitive impairment, medication adherence may be challenging, and gastrointestinal side effects could lead to dehydration or nutritional deficiencies